CMMB

Chemomab Therapeutics
CMMB

10 hedge funds and large institutions have $1.03M invested in Chemomab Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

more ownership

Funds ownership: →

less funds holding

Funds holding: →

less repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less capital invested

Capital invested by funds: $ → $

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
10
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$78.9K
2
+$43.1K
3
+$5.98K

Top Sellers

1
-$1.09M
2
-$824K
3
-$671K
4
KPWS
Kestra Private Wealth Services
Texas
-$36.2K
5
BFM
Boothbay Fund Management
New York
-$30.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
SFM
1
Sphera Funds Management
Israel
$472K
Morgan Stanley
2
Morgan Stanley
New York
$237K
IC
3
Ikarian Capital
Texas
$140K
SCM
4
Stonepine Capital Management
Oregon
$78.9K
Jane Street
5
Jane Street
New York
$56.6K
RhumbLine Advisers
6
RhumbLine Advisers
Massachusetts
$25K
BNP Paribas Financial Markets
7
BNP Paribas Financial Markets
France
$15.1K
GI
8
GAMMA Investing
California
$1.75K
UBS Group
9
UBS Group
Switzerland
$260
SS
10
SBI Securities
Japan
$68
O
11
OrbiMed
New York
–
YLHM
12
Yelin Lapidot Holdings Management
Israel
–
KPWS
13
Kestra Private Wealth Services
Texas
–
BFM
14
Boothbay Fund Management
New York
–
JP Morgan Chase
15
JP Morgan Chase
New York
–